Sutro Biopharma (STRO) Competitors

Sutro Biopharma (NASDAQ:STRO) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, community ranking, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

Does the media favor STRO or SOPH?

In the previous week, Sutro Biopharma had 1 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 6 mentions for Sutro Biopharma and 5 mentions for SOPHiA GENETICS. Sutro Biopharma's average media sentiment score of 0.55 beat SOPHiA GENETICS's score of 0.46 indicating that Sutro Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sutro Biopharma	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SOPHiA GENETICS	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do insiders & institutionals have more ownership in STRO or SOPH?

97.0% of Sutro Biopharma shares are held by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are held by institutional investors. 5.9% of Sutro Biopharma shares are held by company insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Which has higher valuation and earnings, STRO or SOPH?

SOPHiA GENETICS has higher revenue and earnings than Sutro Biopharma. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sutro Biopharma	$62.04M	1.43	-$106.79M	-$3.02	-0.35
SOPHiA GENETICS	$65.17M	3.10	-$78.98M	-$0.95	-3.19

Which has more volatility and risk, STRO or SOPH?

Sutro Biopharma has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.

Does the MarketBeat Community favor STRO or SOPH?

Sutro Biopharma received 113 more outperform votes than SOPHiA GENETICS when rated by MarketBeat users. However, 70.37% of users gave SOPHiA GENETICS an outperform vote while only 63.77% of users gave Sutro Biopharma an outperform vote.

Company	Underperform	Outperform
Sutro Biopharma	Outperform Votes 132 63.77%	Underperform Votes 75 36.23%
SOPHiA GENETICS	Outperform Votes 19 70.37%	Underperform Votes 8 29.63%

Is STRO or SOPH more profitable?

Sutro Biopharma has a net margin of -77.01% compared to SOPHiA GENETICS's net margin of -110.71%. SOPHiA GENETICS's return on equity of -55.06% beat Sutro Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sutro Biopharma	-77.01%	-101.89%	-28.69%
SOPHiA GENETICS	-110.71%	-55.06%	-38.33%

Do analysts prefer STRO or SOPH?

Sutro Biopharma presently has a consensus target price of $6.63, indicating a potential upside of 527.96%. SOPHiA GENETICS has a consensus target price of $6.80, indicating a potential upside of 124.35%. Given Sutro Biopharma's higher probable upside, analysts clearly believe Sutro Biopharma is more favorable than SOPHiA GENETICS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sutro Biopharma	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22
SOPHiA GENETICS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Sutro Biopharma beats SOPHiA GENETICS on 10 of the 17 factors compared between the two stocks.